Gestational diabetes & diabetes in pregnancy
Metabolomic and genetic architecture of gestational diabetes subtypes
Authors' conclusion
This study demonstrates that physiological GDM subtypes differ in their metabolome and genetic architecture. These findings require replication in additional cohorts, but suggest that these differences may contribute to subtype-related adverse pregnancy outcomes.
Study context
- Population
- Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study participants who underwent an OGTT at ≈28 weeks' gestation; Gestational diabetes mellitus (GDM) defined retrospectively by IADPSG/WHO criteriametabolomics 3463
- Exposure
- Insulin-deficient GDM vs insulin-resistant GDM vs normal glucose tolerance
- Outcome
- Metabolome and genetic architecture of GDM subtypes
Methodological detailssecondary analysis of the HAPO study, metabolomic analyses, genome-wide association studies
- Secondary analysis of the HAPO study
- Metabolomic analyses
- Genome-wide association studies
Main finding
As reported in the abstract
- Fasting metabolites uniquely associated with insulin-deficient GDM, incl. 22 medium- and long-chain acylcarnitines
- 33
- Metabolites uniquely associated with insulin-resistant GDM, incl. branched-chain amino acids and their metabolites
- 23
- GCKR rs1260326 and insulin-resistant GDM
- p=1.36×10-13, OR 1.60
- MTNR1B rs10830963 and insulin-resistant GDM
- p=1.22×10-9, OR 1.49
Observational data: associations, not effects.
Further findings
GWAS for GDM overall
- MTNR1B rs10830963
- P = 3.43×10-18, OR 1.55
- GCKR rs1260326
- P = 5.17×10-13, OR 1.43
GCKR rs1260326 and metabolites associated with insulin-resistant GDM
- Fasting metabolites associated
- 8 of 25
- 1 h metabolites associated
- 10 of 41
Original publication
Metabolomic and genetic architecture of gestational diabetes subtypes. Diabetologia. Published 17 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →